First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
The transaction is expected to close in Q2 FY 2026
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
Subscribe To Our Newsletter & Stay Updated
